MinervaX, a Danish biotechnology company, has joined forces with contract development and manufacturing organisation (CDMO) Wacker Biotech for the manufacturing of MinervaX’s active protein ingredients for its Group B Streptococcus (GBS) vaccine.
Biopharmaceutical company Celltrion has solidified its presence in the Latin American pharmaceutical market with a series of successful public tender wins in Peru.
The National Institute for Health and Care Excellence (NICE) has recommended Idorsia UK’s QUVIVIQ (daridorexant) to treat chronic insomnia in adults.
Eli Lilly and Company (Lilly) has completed the acquisition of clinical-stage biopharmaceutical firm Versanis Bio.
BioCryst Pharmaceuticals has signed a collaboration agreement with Er-Kim Pharmaceuticals for commercialising ORLADEYO (berotralstat) in Turkey.
The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.
Intercept Pharmaceuticals has received orphan drug designation from US Food and Drug Administration (FDA) for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate to treat individuals with primary biliary cholangitis (PBC).
Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial disease.
California-based AcelRx Pharmaceuticals has completed the divestment of DSUVIA to Alora Pharmaceuticals.
The US Food and Drug Administration (FDA) has granted fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 that helps to lower triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.